Eckhard Brueggemann - STADA Arzneimittel Insider

STADA Arzneimittel Aktiengesellschaft -- USA Stock  

USD 96.6  0.00  0.00%

Member of the Supervisory Board

Dr. Eckhard Brueggemann was Member of the Supervisory Board of STADA Arzneimittel AG from August 24 2009 August 26 2016. From February 5 2001 to August 24 2009 he occupied the position of Chairman of the Supervisory Board at the Company. Before that he served as Member of the Supervisory Board at STADA Arzneimittel AG from 1997. He started a medical practice in Herne Germany in 1972. From 1983 to 1993 he was Chairman of the German Association of General Practitioners. Since 1993 he was a Board Member of the Federal Association of German Family Doctors. In 1997 he was elected to the Supervisory Board of STADA Arzneimittel AG. He completed his medical studies in Marburg and Essen Germany and Innsbruck Austria and is a specialist in general medicine.
Age: 75  Executive Since 2009  Ph.D    
49 6101 6030  http://www.stada.de

Management Efficiency

The company has return on total asset (ROA) of 4.99 % which means that it generated profit of $4.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 9.63 % meaning that it generated $9.63 on every $100 dollars invested by stockholders.
The company has accumulated 1.72 B in total debt with debt to equity ratio (D/E) of 129.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. STADA Arzneimittel Aktiengesellschaft has Current Ratio of 1.24 suggesting that it may have difficulties to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. STADA Arzneimittel Aktiengesellschaft (STDAF) is traded on OTC Market in USA. It is located in Bad Vilbel, and employs 10,872 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add STADA Arzneimittel Aktiengesellschaft to your portfolio

Top Management

STADA Arzneimittel A Leadership Team
Carl Oetker, Executive
JanNicolas Garbe, Executive
Dieter Koch, Executive
Eckhard Brueggemann, Executive, Ph.D
Mark Keatley, CFO
Ralph Grobecker, Managing Director, Ph.D
Martin Abend, Chairman, Ph.D
Matthias Wiedenfels, Executive, Ph.D
Arnold Hertzsch, Executive, Ph.D
Halil Duru, Executive
Tina Mueller, Executive
Engelbert Willink, Chairman
Barthold Piening, Executive, Ph.D
Helmut Kraft, CFO
Ute Pantke, Executive, Ph.D
Hartmut Retzlaff, Chairman
Bernhard Duettmann, CFO
Claudio Albrecht, Chairman, Ph.D
Michael Siefke, Executive
Leslie Iltgen, President
Eric Cornut, Executive
Jens Steegers, Executive
Birgit Kudlek, Executive, Ph.D
Guenter Au, Chairman, Ph.D
Constantin Meyer, Executive
Rolf Hoffmann, Executive, MBA
Markus Metzger, Director
Benjamin Kunstler, Executive
Gunnar Riemann, Executive, Ph.D
Bruno Schick, Executive

Stock Performance

STADA Arzneimittel Performance Indicators